â– LECTURE OVERVIEW: Acute stroke represents a neurological emergency. Timely differentiation between ischemic and hemorrhagic profiles is critical to determine the therapeutic pathway.
â– CLINICAL DYNAMICS:
1. Ischemic Stroke (85% of cases):
- Origin: Caused by thrombotic or embolic occlusion of a cerebral artery, most commonly the Middle Cerebral Artery (MCA).
- Cascade: Focal tissue ischemia triggers an ischemic cascade, depleting ATP, causing cellular depolarization, toxic glutamate release, and ultimate necrotic cell death.
2. Hemorrhagic Stroke (15% of cases):
- Origin: Caused by the rupture of a blood vessel in the brain parenchyma (intracerebral hemorrhage, often from long-standing hypertension eroding Charcot-Bouchard aneurysms) or into the subarachnoid space (subarachnoid hemorrhage, often from a ruptured saccular berry aneurysm).
â– BIOCHEMICAL MECHANISMS:
At the molecular level, enzyme kinetics govern reaction rates. Competitive inhibitors raise apparent Michaelis constants without changing maximum speed, whereas noncompetitive inhibitors decrease maximum speed directly.
â– EVIDENCE-BASED GUIDELINE SYNOPSIS:
Recent international multi-center guidelines emphasize starting therapeutic interventions immediately upon diagnosis to minimize long-term target organ strain.
[HY-BOARD-1050]
🌟 Dynamic Clinical Key:
A non-contrast head CT scan is the absolute first-line screening diagnostic of choice. Because acute ischemia is initially invisible on CT, the main purpose is to rule out hemorrhagic stroke before administering fibrinolytic agents like recombinant tPA, which would be fatal if given during active intracranial hemorrhage. Focus on rate-limiting regulatory steps for pharmacological design. Consult updated medical consensus reports to align treatment protocols with modern precision standards.